Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0GRWAH
ADC Name	Her3-ADC-21 (DAR4)
Synonyms	Her3 ADC 21 (DAR4) Click to Show/Hide
Organization	Suzhou Medilink Therapeutics Ltd.
Drug Status	Investigative
Indication	In total 2 Indication(s) Colon cancer [ICD11:2B90] Investigative Lung cancer [ICD11:2C25] Investigative
Drug-to-Antibody Ratio	4.1
Structure
	3D MOL	2D MOL
Antibody Name	Anti-Her3 mAb 202-2-1		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-3 (ERBB3)		Antigen Info
Payload Name	Undisclosed
Linker Name	Her3-ADC-21(DAR4) linker

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 29.92	%	NCI-H358 cells	Minimally invasive lung adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 75.74	%	NCI-H358 cells	Minimally invasive lung adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 29.92% (Day 29)	Low CD276 expression (CD276 +)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 75.74% (Day 29)	Low CD276 expression (CD276 +)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 5 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

References

Ref 1	Bioactive substance conjugate, preparation method therefor and use thereof; 2022-08-18.